Eisai Sues to Protect Aricept
Posted on: Monday, 7 August 2006, 09:00 CDT
Japanese pharmaceutical company Eisai has launched legal action to protect its patent on its Alzheimer's drug Aricept after Mutual Pharmaceutical and United Research Laboratories filed an application with the FDA for a generic version of the product.
Eisai said that it believes that its patent covering the composition of donepezil, the active ingredient in Aricept, is valid until its expiration date of November 25, 2010, and that it intends to "vigorously enforce and defend the patent."
Aricept is an acetylcholinesterase inhibitor and is believed to work by inhibiting the breakdown of acetylcholine, thereby increasing available levels of this chemical in the brain.
Separately, Eisai also recently announced that it has come to an agreement with Israeli drug maker Teva to end a collaboration focused on the Parkinson's drug rasagiline (Azilect).
Source: Datamonitor
Related Articles
- U.S. Federal Circuit Court of Appeals Fully Upholds Eisai's Favorable Ruling in Aciphex(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals and Dr. Reddy's Laboratories
- Eisai Acquires Ligand Cancer Drugs in $205 Million Deal
- Street Pulse: Guarding Aricept: Eisai CEO
- Generics Will Benefit As 75 Drugs Lose Their Patent Protections
- Eisai Reports Fatalities in Study of Alzheimer's Drug
- Eleven patients die in Eisai drug trial
- A Home of Its Own ; Plans for a New U.S. Base Signify Drug Maker Eisai's Rise
- Eisai Forms Alliance With Swedish Firm for Alzheimer Drug Research
- Merrion Pharmaceuticals, Inc. Is Issued a United States Drug Delivery System Patent
 |
 |
User Comments (0)
RSS Feeds